C19-IG 20%
/ Grifols
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 21, 2023
Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial.
(PubMed, EClinicalMedicine)
- P3 | "Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Grifols."
Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
February 25, 2022
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
(clinicaltrials.gov)
- P3 | N=465 | Terminated | Sponsor: Grifols Therapeutics LLC | N=801 ➔ 465 | Recruiting ➔ Terminated; Study Stopped for Futility
Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 20, 2021
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
(clinicaltrials.gov)
- P3; N=801; Recruiting; Sponsor: Grifols Therapeutics LLC; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR
April 19, 2021
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
(clinicaltrials.gov)
- P3; N=801; Not yet recruiting; Sponsor: Grifols Therapeutics LLC
New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR
1 to 4
Of
4
Go to page
1